Mutations in the PIK3CA gene are present in about 4% to 36% of cancers such as breast, ovarian, endometrial and colorectal cancer, among others.

Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in ...

Inavolisib (Itovebi) plus fulvestrant and palbociclib (Ibrance) led to a statistically significant and clinically meaningful benefit in progression-free survival (PFS) vs fulvestrant and palbociclib ...

PIK3CA mutations are poor prognostic indicators in advanced breast cancer. Addition of the PI3K inhibitor inavolisib to palbociclib–fulvestrant might improve outcomes. New research findings are ...

The FDA has approved Genentech’s inavolisib (Itovebi) in combination with the CDK4/6 inhibitor palbociclib and the oestrogen-receptor antagonist fulvestrant for endocrine-resistant, PIK3CA ...